Diabetic Foot Amputation Prevention: Integrating Standard Care and Hyperbaric Oxygen Therapy

Dr. Asif Shahariar
Critical Care, Drugs, Genetics, Medicine, Patient

30

Mar 26

Abstract
Diabetic foot complications remain a leading cause of nontraumatic lower-extremity amputation worldwide. Prevention requires an integrated program of tight glycemic control, risk stratification, vascular assessment, wound care, infection control, patient education, and timely revascularization. Hyperbaric oxygen therapy (HBOT) is an adjunctive option for selected, nonhealing, ischemic diabetic foot ulcers that can help salvage threatened limbs when used alongside standard care. This article reviews mechanisms, evidence, operational considerations (cost and throughput), real-world success examples, and comprehensive preventive strategies.

Introduction

Diabetes mellitus increases risk for peripheral neuropathy, peripheral arterial disease (PAD), and infection the three principal drivers of foot ulcers and subsequent amputation. Preventing amputation means preventing ulceration, detecting and treating wounds early, and salvaging ischemic or infected tissue before limb loss becomes necessary. HBOT has been used as an adjunct for refractory, ischemic diabetic foot ulcers for decades; clinicians and program planners frequently ask (1) when to use HBOT, (2) how it works, and (3) whether investment in a hyperbaric service is justified. This article synthesizes the clinical evidence, explains the physiology, and provides practical operational and cost information for clinical teams and health system managers.1–6

Diabetic Foot Pathophysiology & Amputation

Three pathophysiologic processes converge in the diabetic foot: sensory/autonomic neuropathy (loss of pain, abnormal foot mechanics), micro- and macrovascular disease (reduced perfusion), and impaired wound healing plus susceptibility to infection. Minor trauma or pressure leads to skin breakdown → ulcer formation → colonization and deep infection (soft tissue or bone). If perfusion and infection are not corrected, tissue necrosis progresses, sometimes leading to major (above- or below-knee) amputation. Effective prevention is therefore multi-modal: patient education, mechanical offloading, vascular evaluation (and revascularization when indicated), infection control (antibiotics, debridement), and optimized metabolic control.7–9

Hyperbaric Oxygen Therapy (HBOT)

HBOT consists of the patient breathing 100% oxygen while inside a sealed chamber at greater than atmospheric pressure (commonly 2.0–2.5 atmospheres absolute [ATA]). Treatments are typically 60–120 minutes per session, delivered once daily (5 days/week) for a course that may range from 20 to 40 sessions for chronic wounds; some protocols prescribe up to 60 sessions depending on response and indication. Chambers are either monoplace (single-patient, often a rigid capsule) or multiplace (a room-type chamber that can accommodate multiple patients and treating staff).2,5,10,11

HBOT in Amputation Prevention

HBOT augments tissue oxygenation and influences a set of biologic processes essential for wound resolution:

  1. Correcting local hypoxia. Under pressure, plasma carries much more dissolved oxygen; tissue oxygen tension rises in otherwise hypoxic wound beds, restoring oxygen-dependent cellular processes required for repair.12,13
  2. Angiogenesis (new blood vessel formation). Intermittent hyperoxia followed by return to normoxia stimulates growth factors (e.g., VEGF) and endothelial proliferation, promoting granulation and capillary ingrowth into ischemic tissue — important for long-term wound perfusion.12,21
  3. Enhanced collagen synthesis and fibroblast activity. Fibroblasts require oxygen for collagen deposition and matrix remodeling; HBOT re-enables this function in hypoxic wounds.21
  4. Improved host immune function and antimicrobial effects. Oxygen enhances neutrophil respiratory burst and bacterial killing (especially for anaerobic organisms) and can potentiate some antibiotics. HBOT also exerts direct bacteriostatic/bactericidal effects in certain pathogens.13
  5. Reduction of edema and ischemia-reperfusion injury. Vasoconstriction in well-oxygenated tissues reduces edema while maintaining oxygen delivery via higher plasma O₂ content; this helps decrease interstitial pressure and improve microcirculatory flow.12

These mechanisms together can halt progression of unhealthy tissue, allow infected or necrotic tissue to be debrided more effectively, and in carefully selected patients help wounds heal without requiring major amputation.12–14

Clinical Evidence of HBOT

  • Short-term healing benefit. Several meta-analyses and systematic reviews report that HBOT increases short-term ulcer healing rates and can reduce major amputation rates in certain studies, especially when used as an adjunct in refractory, ischemic ulcers. However, quality and heterogeneity of trials limit certainty for long-term outcomes.1,3,5,15
  • Guideline recommendations (judicious use). International and national wound-care guideline groups (including Undersea and Hyperbaric Medical Society and IWGDF guidance) recommend considering HBOT as adjunctive therapy for selected nonhealing, ischemic diabetic foot ulcers after optimal standard care and vascular assessment have been performed. HBOT is not recommended for uncomplicated superficial ulcers.2,8,16
  • Health-system stances vary. Some health systems (for example NHS England guidance) emphasize selective use and caution, reflecting both evidence limits and cost/availability considerations.1

HBOT is a useful adjunct therapy in selected, refractory cases but is not a substitute for standard-of-care measures (offloading, debridement, antibiotics, revascularization).1–3,8,16

HBOT Candidates

  1. Patient selection. Persistent, nonhealing diabetic foot ulcers (Wagner grade ≥3, ischemic component, refractory after 4–6 weeks of optimal care) or tissue at imminent risk despite revascularization are typical candidates.2,16
  2. Adjunct to standard care. HBOT is added after thorough vascular assessment (ABI, toe pressures, doppler/angiography) and either concurrent with revascularization or when revascularization is not feasible. It augments perfusion at the microvascular level and helps control infection, enabling limb salvage attempts that might otherwise fail.2,8,12,22
  3. End point. Successful courses lead to wound granulation and progressive healing, reducing the need for progressive surgical amputation, or conversion of an otherwise major amputation to a more limited, limb-sparing procedure. Several program series and case series report limb salvage after HBOT courses when other measures were insufficient.14,22

Operational Considerations

Throughput depends on chamber type, session length, staffing and scheduling efficiencies:

  • Session duration and frequency. Typical HBOT sessions run 90–120 minutes (including compression/decompression and air brakes), commonly once daily, five days per week. Some conditions require twice-daily sessions, but diabetic wounds are usually once daily.10,11
  • Monoplace chamber throughput. Can accommodate 4-6 patients per day within 8-12 hours of the day.10,11
  • Multiplace chamber throughput. A multiplace chamber can treat multiple patients simultaneously (often 2–6 or more depending on chamber size).5,11
  • Real-world constraint. Patient monitoring, oxygen mask/hood setup, staff availability, and the need for clinical observation (especially for infected or comorbid patients) often limit maximal throughput.1,10

Types of Hyperbaric Chamber

  • Soft-shell / mild (wellness) units: Not medical-grade; limited pressure, not appropriate for systemic HBOT for diabetic foot ulcer. 4,18
  • Hard monoplace chambers (medical grade) 18,19
  • Multiplace chambers 11,19

A realistic startup budget for a small clinical HBOT program is commonly several hundred thousand dollars to over a million, depending on chamber choice and facility requirements.11,18,19 The additional compliance to maintain such chambers requires continuous supply of oxygen, maintenance, staff, and certification. 4,18,19

Success Stories and International Experience

Published case series and program reports from multiple countries describe limb salvage with HBOT when added to comprehensive wound programs:

  • United States (tertiary centers). Several academic hyperbaric centers report improved healing rates and limb salvage among selected patients referred for refractory ischemic diabetic foot ulcer after aggressive standard care and vascular evaluation.10,12
  • Europe and UK. NHS guidance (England) recommends selective use; regional HBOT centers report limb salvage in series of patients with otherwise nonhealing ischemic ulcers.1,16
  • Middle East and Asia (case series). Case reports and national series from countries including Turkey, Iran and India describe successful avoidance of major amputation following HBOT in patients who had failed conventional care.14,22
  • Brazil and other middle-income settings. Published program evaluations and case reports show HBOT used as part of multidisciplinary limb-salvage services with favorable outcomes in selected cohorts, though access and reimbursement vary.17,22

Caveat: Most evidence is observational or from heterogeneous randomized trials; while individual and program outcomes are encouraging, randomized evidence quality is variable. Systematic reviews note beneficial signals for wound healing and some reduction in major amputation but call for higher-quality trials.1,3,15

Risks and Contraindications

  • Absolute contraindication: untreated pneumothorax.11
  • Common adverse events: middle ear barotrauma, sinus barotrauma, transient myopia, claustrophobia, oxygen toxicity (rare seizure).11,20
  • Monitoring needs: glucose monitoring (risk of hypoglycemia during sessions), watch for carbon dioxide retention in patients with severe COPD, and medication reconciliation for any oxygen-sensitive drugs.11

HBOT- Prevention-first Ecosystem

HBOT is one tool in a limb-salvage toolbox. A comprehensive prevention program must include:

  1. Primary prevention / patient education. Daily foot inspection, proper footwear, early reporting of blisters or lesions, glycemic control and smoking cessation.7
  2. Regular screening and risk stratification. Annual foot exam, monofilament sensory testing, vascular assessment (ABI, toe pressures), and podiatry access for high-risk patients.7,16
  3. Prompt wound management. Sharp debridement, appropriate dressings, infection control (targeted antibiotics), pressure off-loading (total contact casting or removable walkers), and wound bed preparation.8,16
  4. Vascular optimization. Arterial imaging and timely revascularization when indicated (endovascular or open surgical) revascularization remains the single most important limb-salvage intervention in ischemic limbs.8,22
  5. Multidisciplinary limb-salvage teams. Podiatry, vascular surgery, infectious disease, endocrinology, wound care nursing, and, where available, hyperbaric medicine. Coordinated care reduces time to appropriate interventions and improves outcomes.8,22
  6. Post-healing surveillance and footwear programs. Custom insoles and regular follow-up to prevent recurrence.7

Conclusion

Preventing diabetic foot amputation is fundamentally about preventing ulcers, early detection, optimized wound and vascular care, and aggressive infection control. HBOT is an evidence-supported adjunct for selected, refractory, ischemic diabetic foot ulcers and can contribute to limb salvage when integrated into a multidisciplinary pathway. The scientific rationale is robust (correction of tissue hypoxia, angiogenesis, immune enhancement), but evidence quality limits universal recommendation therefore HBOT should be used judiciously, with careful patient selection and within programs that can deliver standard-of-care wound and vascular interventions. Operationally, chambers range from low-cost wellness devices (unsuitable for medical use) to high-capital medical systems; throughput and staffing must be planned to ensure clinical safety and fiscal sustainability. When used appropriately, HBOT has helped many healthcare programs avoid major amputations and restore function but it is not a replacement for the basic pillars of diabetic foot prevention.

Author of this article

Dr. Asif Shahariar, MBBS, CCD(Birdem), PGT, Medical Officer, Aryan Hospital & Diagnostic Centre

References

  1. National Health Service (England). Hyperbaric oxygen therapy for diabetic lower-limb ulceration (all ages). NHS England; Apr 2019. Accessed 2025. https://www.england.nhs.uk/wp-content/uploads/2019/04/Hyperbaric-oxygen-therapy-for-diabetic-lower-limb-ulceration-all-ages.pdf.
  2. Undersea and Hyperbaric Medical Society (UHMS). HBO₂ Indications (summary). UHMS. Accessed 2025. https://www.uhms.org/resources/featured-resources/hbo-indications.html.
  3. Oley MH, [et al.]. Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers — systematic review and analysis. J Wound Care / Review. 2024. (Review article summarizing short-term healing benefit and heterogeneity of trials). PubMed Central.
  4. HyperbaricPro. How Much Does a Hyperbaric Chamber COST? Published 2025. Accessed 2025. https://www.hyperbaricpro.com/how-much-does-a-hyperbaric-chamber-cost/.
  5. Ortega MA, et al. A general overview on hyperbaric oxygen therapy. Front Med (Lausanne). 2021; (review, mechanisms and session protocols). doi: See PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465921/.
  6. Kirby JP, et al. Hyperbaric oxygen indications and diabetic foot ulcers. Wound Care Clin. 2019; (discussion of referral and practical use). PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690299/.
  7. International Working Group on the Diabetic Foot (IWGDF). Wound-healing guidelines; 2019/2020. Accessed 2025. https://iwgdfguidelines.org/wp-content/uploads/2021/03/06-Wound-Healing-Guideline.pdf.
  8. Rayman G, et al. Guidelines on use of interventions to enhance healing — wound care and diabetic foot. Diabetic Medicine. 2020. (Recommendations include judicious use of HBOT). PubMed.
  9. Bhutani S, et al. Hyperbaric oxygen and wound healing mechanisms. Clin Plast Surg. 2012; (review of oxygen gradient and angiogenesis). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495382/.
  10. Michigan Medicine (University of Michigan). What to know before receiving HBOT. Mar 3, 2020. (Session times, typical regimen). https://www.michiganmedicine.org/health-lab/what-know-receiving-hyperbaric-oxygen-chamber-therapy.
  11. Selections from modern hyperbaric program operational literature and market reports (installation, throughput and staffing) — industry summaries and market reports. Huelight USA. Hyperbaric Chamber Cost. Mar 22, 2024. https://huelightusa.com/cost-of-hyperbaric-chamber/.
  12. Memar MY, et al. Hyperbaric oxygen therapy: antimicrobial mechanisms and modulation of the immune response. Eur J Clin Microbiol Infect Dis. 2019; (review).
  13. Bishop AJ, et al. Diabetic foot ulcers and HBOT clinical outcomes — systematic and primary studies. Wound Repair Regen. 2012; (variable results in trials). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7950353/.
  14. Kaya A, et al. Can major amputation rates be decreased in diabetic foot disease with HBOT? Diabet Foot Ankle. 2008; (series showing limb salvage signals). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899043/.
  15. Wenhui L, et al. Hyperbaric oxygen therapy for chronic diabetic foot ulcers — meta-analysis (2021). Wound Care Journal. (Cochrane-style review noting short-term benefits).
  16. Huang ET, et al. Clinical practice guideline for HBOT in diabetic foot ulcers (UHMS guideline summary). 2015. https://www.uhms.org/images/CPG/UHM_42-3_CPG_for_DFU.pdf.
  17. Kirby JP. Hyperbaric oxygen indications: diabetic foot ulcers and practical referral guidance. PMCID article. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690299/.
  18. HPOTech / HPO industry cost calculator and summaries (vendor planning tool). https://www.hpotech.com/cost-calculator/.
  19. Market reports and startup planning sources summarizing monoplace vs multiplace capital costs (industry market research 2024–2025).
  20. Shah J, et al. Standard HBOT protocols for diabetic wounds — 2.0–2.4 ATA for 90 min/day for 30–40 days. Hyperbaric Medicine. 2010. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601859/.
  21. Memar MY, et al. Mechanisms of antimicrobial and wound-healing effects of HBOT. Int J Infect Dis. 2019.
  22. Case reports and country-level program reports (Turkey, Iran, Brazil) showing limb salvage after HBOT when combined with standard care. (Representative examples cited throughout text.)